body composition is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-11-19. Where a claim depends on a specific study, the study is described rather than over-claimed.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Documentation plays a practical role in maintaining consistent results across laboratories. Certificates of analysis list purity, identity, and testing methods, and batch numbers allow comparisons between lots. Records of storage temperature and handling history help investigators interpret unexpected findings. When a sample behaves anomalously, reviewing that documentation often reveals whether the cause lies in the material or in the assay conditions.
Retatrutide is an investigational synthetic peptide that acts as an agonist at three distinct G protein-coupled receptors. It combines activity at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor within a single molecule. This multi-receptor profile distinguishes it from earlier incretin-based compounds that engage one or two of these pathways. Researchers designed the molecule to test whether simultaneous activation produces greater metabolic effects than single or dual agonism alone.
The peptide backbone is chemically modified to resist rapid enzymatic breakdown in the body. A fatty acid side chain promotes binding to serum albumin, which slows renal clearance and supports an extended circulation time. These modifications allow less frequent administration than would be possible with an unmodified peptide. The precise contribution of glucagon receptor activation to the overall metabolic effect remains an area of active investigation, because glucagon raises glucose while also increasing energy expenditure.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilized solid form |
| Solubility | Soluble in water | Dissolves readily in aqueous media |
| Typical storage | -20 degrees Celsius or colder | Frozen, protected from light |
| Primary assay | Reversed-phase LC-MS | Separates and identifies the peptide |
| Common synonyms | LY3437943; triple agonist | Research designations |
Body composition is assessed with dual-energy X-ray absorptiometry or comparable methods, which separate fat mass from lean mass. Reported losses include both compartments, and the ratio between them is a subject of ongoing analysis rather than a settled result. Waist circumference, blood pressure, and lipid panels are collected as supporting measures. Resting energy expenditure and substrate oxidation are measured in smaller mechanistic studies, where glucagon receptor activity is expected to matter. These substudies are typically short and small, so their findings carry wide uncertainty.
Interpretation depends on study phase and duration. Phase 2 programs are powered for weight and safety signals, not for cardiovascular or renal outcomes, which require event-driven designs. Gastrointestinal events such as nausea, diarrhea, vomiting, and constipation are the most frequently reported adverse effects and tend to cluster around dose escalation. Small increases in heart rate have been described. Because follow-up after treatment discontinuation is limited, questions about weight regain and durability are open rather than answered.
Clinical development has progressed through phase 2 trials in adults with obesity and type 2 diabetes, with phase 3 programs reported as ongoing. Reported outcomes include reductions in body weight and improvements in glycemic measures over defined treatment periods. Whether these effects translate into durable benefits after treatment ends remains an open question. Long-term safety data across broad populations are not yet complete, and regulatory decisions have not been announced.
Retatrutide is an investigational synthetic peptide engineered to activate three distinct hormone receptors within a single molecule. It targets the glucose-dependent insulinotropic polypeptide receptor, the glucagon-like peptide-1 receptor, and the glucagon receptor simultaneously. This triagonist design distinguishes it from earlier incretin-based compounds that act on one or two of these pathways. Structural modifications relative to native gut hormones extend its residence time in circulation. The molecule remains under clinical evaluation and is not approved for any indication.
Receptor activation produces downstream effects that differ by tissue. GLP-1 receptor signaling influences appetite regulation and insulin secretion in a glucose-dependent manner. GIP receptor activity contributes to metabolic handling of nutrients and may modulate adipose tissue. Glucagon receptor engagement raises energy expenditure and promotes hepatic lipid turnover, though the balance among these actions in humans is still being characterized. Preclinical models showed reductions in body weight and improved glycemic markers.
=== Alcohol === Alcohol has biological, mental, and social effects which influence the consequences of using alcohol for pain. Moderate use of alcohol can lessen certain types of pain in certain circumstances. The majority of its analgesic effects come from antagonizing NMDA receptors, similarly to ketamine, thus decreasing the activity of the primary excitatory (signal boosting) neurotransmitter, glutamate. It also functions as an analgesic to a lesser degree by increasing the activity of the primary inhibitory (signal reducing) neurotransmitter, GABA. Attempting to use alcohol to treat pain has also been observed to lead to negative outcomes including excessive drinking and alcohol use disorder.
14 October – NASA launches the Europa Clipper from Kennedy Space Center, which will study the Jovian moon Europa while orbiting Jupiter. 15 October – Physicists and Researchers from the Institute of Nuclear Physics of the Polish Academy of Sciences achieve the first coherent picture of atomic nuclei made from only quarks and gluons, fusing this picture with the model of nuclei made from protons and neutrons. 16 October – Researchers at the University of Birmingham Medical School encounter a human cadaver with three penises. 17 October Scientists observe a black hole corona using NASA's Imaging X-ray Polarimetry Explorer, and determine its shape for the first time. A study of 25 crowdsourced ideas aimed at reducing political polarisation in the United States is published in the journal Science. Scientists build the world's smallest quantum computer using a single photon. 19 October – Researchers develop a plant-based food supplement to protect bees' brains from neurotoxins. 23 October Physicists observe a "black hole triple" for the first time. Astronomers using NASA/ESA's James Webb Space Telescope detect the first brown dwarf candidates outside the Milky Way in NGC 602. Scientists works on ways to remove CO2 from the air as levels rise. One method, called direct air capture, uses a strong material (COF with amines) that can absorb and release CO2 at low temperatures. It fits into machines that already capture CO2 from factories. 28 October – A study of the Uranian moon Miranda finds that it may contain a deep ocean of water below its surface.
=== Neonicotinoids === Neonicotinoids are a class of neuro-active insecticides chemically similar to nicotine, with much lower acute mammalian toxicity and greater field persistence. These chemicals are acetylcholine receptor agonists. They are broad-spectrum systemic insecticides, with rapid action (measured in minutes or hours). They are applied as sprays, drenches, seed and soil treatments. Treated insects exhibit leg tremors, rapid wing motion, stylet withdrawal (aphids), disoriented movement, paralysis and death. Imidacloprid, of the neonicotinoid family, is the most widely used insecticide in the world. In the late 1990s neonicotinoids came under increasing scrutiny over their environmental impact and were linked in a range of studies to adverse ecological effects, including honey-bee colony collapse disorder (CCD) and loss of birds due to a reduction in insect populations. In 2013, the European Union and a few non EU countries restricted the use of certain neonicotinoids. and its potential to increase the susceptibility of rice to planthopper attacks.
Sources: en.wikipedia.org
== Pathophysiology == The main etiologic factor of ACC is unknown, although families with Li–Fraumeni syndrome, caused by an inherited inactivation mutation in TP53, have increased risk. Several genes have been shown to be recurrently mutated, including TP53, CTNNB1, MEN1, PRKAR1A, RPL22, and DAXX. The telomerase gene TERT is often amplified while ZNRF3 and CDKN2A are often homozygously deleted. The genes h19, insulin-like growth factor II (IGF-II), and p57kip2 are important for fetal growth and development. They are located on chromosome 11p. Expression of the h19 gene is markedly reduced in both nonfunctioning and functioning adrenal cortical carcinomas, especially in tumors producing cortisol and aldosterone. Also, a loss occurs of activity of the p57kip2 gene product in virilizing adenomas and adrenal cortical carcinomas. In contrast, IGF-II gene expression has been shown to be high in adrenal cortical carcinomas. Finally, c-myc gene expression is relatively high in neoplasms, and it is often linked to poor prognosis. Bilateral adrenocortical tumors are less common than unilateral. The majority of bilateral tumours can be distinguished according to size and aspect of the nodules: primary pigmented nodular adrenocortical disease, which can be sporadic or part of Carney complex, and primary bilateral macro nodular adrenal hyperplasia.Metastasis is most commonly to the liver and lung.
== History == In October 1967, Techtron Pty Ltd merged with Varian Associates. Techtron is a manufacturer of Atomic Absorption Spectrometers and Spectral lamps. In 1982, Varian transferred the Cary UV-Visible product line to Australia. In 1997, Varian bought Chemagnetics, a Colorado-based manufacturer of solid-state NMR spectrometers. In 2002, Varian bought Ansys Technologies, Inc., a California-based manufacturer of In-Vitro Medical Devices. In 2004, Varian Inc bought Magnex Scientific, an Oxford-based manufacturer of high-field magnets. In 2005, Varian bought Polymer Laboratories, a speciality polymer analysis and manufacturing company. In 2006, Varian bought Ion Spec, an FTMS (Fourier Transform Mass Spectrometry) manufacturing company. In 2007, Varian, Inc. bought Analogix, Inc., a company specializing in flash chromatography. In 2008, Varian bought Oxford Diffraction, a British company specializing in X-ray diffraction equipment. On 27 July 2009, Agilent Technologies announced it would buy Varian Inc, for $1.5 Billion. On 14 October 2014, Agilent made the strategic decision to close its NMR business. Agilent entered the NMR business in 2010, with the acquisition of Varian. Several former Varian engineers have continued the business through private ventures, including the probe department spawning the company PhoenixNMR and the software being made open source.
=== Effect of tobacco smoking and nicotine === There is a relationship between smoking tobacco and periodontal disease, wound healing and oral cancers. Nicotine, the major pharmacologically active ingredient in tobacco smoke, lessens a host's ability to defend against bacterial invasion induced by plaque. It is also the ingredient responsible for addiction. Tobacco smoking impairs phagocytic and chemotactic activities of leukocytes and impedes wound healing, specifically by affecting gingival blood flow. Cigarette smokers are more likely to experience destruction of the alveolar bone and periodontal ligament and are at a higher risk of developing periodontal disease. Nicotine and lipopolysaccharides synergistically induce the production of nitric oxide (NO) and PGE2, and increase inducible nitric oxide synthase (iNOS) and COX-2 expression in human periodontal ligament (hPDL) cells. At the cellular level, nicotine reduces the proliferation of red blood cells, macrophages, and fibroblasts and increases platelet adhesiveness. Macroscopically, this affects healing and tissue perfusion due to micro clot formation in the blood vessels. Nicotine also has a sympathomimetic action, stimulating epinephrine and norepinephrine release, which causes vasoconstriction and limits tissue perfusion. Nicotine jeopardises bone formation by inhibiting neovascularization and osteoblastic differentiation.
In a chemical reaction, chemical equilibrium is the state in which both the reactants and products are present in concentrations which have no further tendency to change with time, so that there is no observable change in the properties of the system. This state results when the forward reaction proceeds at the same rate as the reverse reaction. The reaction rates of the forward and backward reactions are generally not zero, but they are equal. Thus, there are no net changes in the concentrations of the reactants and products. Such a state is known as dynamic equilibrium. It is the subject of study of equilibrium chemistry.
Sources: en.wikipedia.org
Orbitrap analyzers are similar to FTMS analyzers. Ions are electrostatically trapped in an orbit around a central, spindle shaped electrode. The electrode confines the ions so that they both orbit around the central electrode and oscillate back and forth along the central electrode's long axis. This oscillation generates an image current in the detector plates which is recorded by the instrument. The frequencies of these image currents depend on the mass-to-charge ratios of the ions. Mass spectra are obtained by Fourier transformation of the recorded image currents. Orbitraps have a high mass accuracy, high sensitivity and a good dynamic range. They are also quite small.
The bacteria might induce systemic resistance in the host plant, so it can better resist attack by a true pathogen. The bacteria might outcompete other (pathogenic) soil microbes, e.g., by siderophores, giving a competitive advantage at scavenging for iron. The bacteria might produce compounds antagonistic to other soil microbes, such as phenazine-type antibiotics or hydrogen cyanide. To be specific, certain P. fluorescens isolates produce the secondary metabolite 2,4-diacetylphloroglucinol (2,4-DAPG), the compound found to be responsible for antiphytopathogenic and biocontrol properties in these strains. The phl gene cluster encodes factors for 2,4-DAPG biosynthesis, regulation, export, and degradation. Eight genes, phlHGFACBDE, are annotated in this cluster and conserved organizationally in 2,4-DAPG-producing strains of P. fluorescens. Of these genes, phlD encodes a type III polyketide synthase, representing the key biosynthetic factor for 2,4-DAPG production. PhlD shows similarity to plant chalcone synthases and has been theorized to originate from horizontal gene transfer. Phylogenetic and genomic analysis, though, has revealed that the entire phl gene cluster is ancestral to P. fluorescens, many strains have lost the capacity, and it exists on different genomic regions among strains. Some experimental evidence supports all of these theories, in certain conditions; a good review of the topic is written by Haas and Defago. Several strains of P. fluorescens, such as Pf-5 and JL3985, have developed a natural resistance to ampicillin and streptomycin.
Acetyl-CoA can be metabolized through the TCA cycle in any cell, but it can also undergo ketogenesis in the mitochondria of liver cells. When glucose availability is low, oxaloacetate is diverted away from the TCA cycle and is instead used to produce glucose via gluconeogenesis. This utilization of oxaloacetate in gluconeogenesis can make it unavailable to condense with acetyl-CoA, preventing entrance into the TCA cycle. In this scenario, energy can be harvested from acetyl-CoA through ketone production. In ketogenesis, two acetyl-CoA molecules condense to form acetoacetyl-CoA via thiolase. Acetoacetyl-CoA briefly combines with another acetyl-CoA via HMG-CoA synthase to form hydroxy-β-methylglutaryl-CoA. Hydroxy-β-methylglutaryl-CoA form the ketone body acetoacetate via HMG-CoA lyase. Acetoacetate can then reversibly convert to another ketone body—D-β-hydroxybutyrate—via D-β-hydroxybutyrate dehydrogenase. Alternatively, acetoacetate can spontaneously degrade to a third ketone body (acetone) and carbon dioxide, which generates much greater concentrations of acetoacetate and D-β-hydroxybutyrate. The resulting ketone bodies cannot be used for energy by the liver so are exported from the liver to supply energy to the brain and peripheral tissues. In addition to fatty acids, deaminated ketogenic amino acids can also be converted into intermediates in the citric acid cycle and produce ketone bodies.
== Early life and education == Meinrad Busslinger was born on 30 July 1952 in Gebenstorf, Switzerland. He grew up in the Swiss town of Zug, where he obtained his grammar school education. From 1972 to 1976, he studied natural sciences at the Swiss Federal Institute of Technology (ETH Zurich), where he majored in biochemistry. During his PhD studies (1976–1981), Busslinger discovered important regulatory elements involved in the transcriptional control of gene expression by investigating the regulation of sea urchin histone genes. He performed his PhD work under the supervision of Max L. Birnstiel at the University of Zurich, from where he received a PhD degree in molecular biology in 1981.
acid 1. (Brønsted–Lowry acid) Any chemical species or molecular entity that acts as a proton donor when reacting with another species, because it loses at least one proton (H+) which is then transferred or 'donated' to the other species, which by definition is a Brønsted–Lowry base. When dissolved in an aqueous solution, a proton donor which increases the concentration of hydronium ion (H3O+) by transferring protons to water molecules may also be called an Arrhenius acid. The term "acid", when not otherwise qualified, often refers implicitly to a Brønsted–Lowry acid. 2. (Lewis acid) Any chemical species or molecular entity that acts as an electron pair acceptor when reacting with another species, forming a covalent bond by accepting a lone pair of electrons donated by the other species, which is known as a Lewis base. This definition was intended as a generalization of the Brønsted–Lowry definition by proposing that acid-base reactions are best viewed as reorganizations of electrons rather than transfers of protons, with the acid being a species that accepts electron pairs from another species either directly or by releasing protons (H+) into the solution, which then accept electron pairs from the other species. The Lewis definition is inclusive of many Brønsted–Lowry acids, though not all: most Lewis acids are not Brønsted–Lowry acids, and most Brønsted–Lowry acids are not Lewis acids. 3. Colloquially, any compound which, when dissolved in water, yields a pH of less than 7.0.
Sources: en.wikipedia.org
Dry powder is kept frozen, commonly at minus twenty degrees Celsius or below. It should be protected from light and moisture. Dissolved material is less stable and is generally used soon after preparation.
Mass spectrometry provides the intact molecular mass, and tandem mass spectrometry can confirm the sequence. Chromatographic retention time adds another layer of confirmation. These methods are usually applied together.
Impurities such as truncated or oxidized forms can alter experimental results. Purity data indicate how much of the sample is the intended molecule. Reputable analysis reports both purity and identity.
Retatrutide is an investigational synthetic peptide that activates three metabolic receptors: GLP-1, GIP, and glucagon. It is being studied for obesity and type 2 diabetes. It has not been approved for clinical use.